Your browser doesn't support javascript.
loading
Long-Term Results of Bioresorbable Vascular Scaffolds in Patients With In-Stent Restenosis: The RIBS VI Study.
Cuesta, Javier; Pérez-Vizcayno, María José; García Del Blanco, Bruno; Bosa, Francisco; Pérez de Prado, Armando; Rumoroso, José Ramón; Romaguera, Rafael; Gutiérrez, Hipólito; García Touchard, Arturo; López-Mínguez, José Ramón; Trillo, Ramiro; de la Torre Hernández, José María; Moreno, Raul; Velázquez, Maite; Moris, Cesar; Kockar, Marcelo Jiménez; Jiménez-Quevedo, Pilar; Bastante, Teresa; Val, David Del; Rivero, Fernando; Alfonso, Fernando.
Affiliation
  • Cuesta J; Hospital Universitario de La Princesa, Madrid, Spain.
  • Pérez-Vizcayno MJ; Fundación Interhospitalaria Investigación Cardiovascular and Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • García Del Blanco B; Hospital Universitario Vall d'Hebrón, Barcelona, Spain.
  • Bosa F; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
  • Pérez de Prado A; Hospital Universitario de León, León, Spain.
  • Rumoroso JR; Hospital de Galdakao, Vizcaya, Spain.
  • Romaguera R; Hospital Universitario de Bellvitge, Barcelona, Spain.
  • Gutiérrez H; Hospital Universitario de Valladolid, Valladolid, Spain.
  • García Touchard A; Hospital Universitario de Puerta de Hierro-Majadahonda, Madrid, Spain.
  • López-Mínguez JR; Hospital Universitario Infanta Cristina, Badajoz, Spain.
  • Trillo R; Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
  • de la Torre Hernández JM; Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Moreno R; Hospital Universitario de La Paz, Madrid, Spain.
  • Velázquez M; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Moris C; Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Kockar MJ; Hospital de la Santa Creu y Sant Pau, Barcelona, Spain.
  • Jiménez-Quevedo P; Fundación Interhospitalaria Investigación Cardiovascular and Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Bastante T; Hospital Universitario de La Princesa, Madrid, Spain.
  • Val DD; Hospital Universitario de La Princesa, Madrid, Spain.
  • Rivero F; Hospital Universitario de La Princesa, Madrid, Spain.
  • Alfonso F; Hospital Universitario de La Princesa, Madrid, Spain. Electronic address: falf@hotmail.com.
JACC Cardiovasc Interv ; 17(15): 1825-1836, 2024 Aug 12.
Article in En | MEDLINE | ID: mdl-39142758
ABSTRACT

BACKGROUND:

In patients with in-stent restenosis (ISR) bioresorbable vascular scaffolds (BVS) provide similar results to drug-coated balloons (DCBs) but are inferior to drug-eluting stents (DES) at 1 year. However, the long-term efficacy of BVS in these patients remains unknown.

OBJECTIVES:

This study sought to assess the long-term safety and efficacy of BVS in patients with ISR.

METHODS:

RIBS VI (Restenosis Intrastent Bioresorbable Vascular Scaffolds Treatment; NCT02672878) and RIBS VI Scoring (Restenosis Intrastent Bioresorbable Vascular Scaffolds Treatment With Scoring Balloon; NTC03069066) are prospective multicenter studies designed to evaluate the results of BVS in patients with ISR (N = 220). The inclusion and exclusion criteria were identical to those used in the RIBS IV (ISR of DES) (Restenosis Intra-stent of Drug-eluting Stents Drug-eluting Balloon vs Everolimus-eluting Stent; NCT01239940) and RIBS V (ISR of bare-metal stents) (Restenosis Intra-stent of Bare Metal Stents Paclitaxel-eluting Balloon vs Everolimus-eluting Stent; NCT01239953) randomized trials (including 249 ISR patients treated with DCBs and 249 ISR patients treated with DES). A prespecified comparison of the long-term results obtained with these treatment modalities (ie, DES, DCBs, and BVS) was performed.

RESULTS:

Clinical follow-up at 3 years was obtained in all (100%) 718 patients. The 3-year target lesion revascularization rate after BVS was 14.1% (vs 12.9% after DCBs [not significant], and 5.2% after DES [HR 2.80; 95% CI 1.47-5.36; P = 0.001]). In a landmark analysis (>1 year), the target lesion revascularization rate after BVS was higher than after DES (adjusted HR 3.41; 95% CI 1.15-10.08) and DCBs (adjusted HR 3.33; 95% CI 1.14-9.70). Very late vessel thrombosis was also more frequent with BVS (BVS 1.8%, DCBs 0.4%, DES 0%; P = 0.03).

CONCLUSIONS:

In patients with ISR, late clinical results of DES are superior to those obtained with DCBs and BVS. Beyond the first year, DCBs are safer and more effective than BVS.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prosthesis Design / Absorbable Implants / Coronary Restenosis Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: JACC Cardiovasc Interv Journal subject: ANGIOLOGIA / CARDIOLOGIA Year: 2024 Document type: Article Affiliation country: Spain Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prosthesis Design / Absorbable Implants / Coronary Restenosis Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: JACC Cardiovasc Interv Journal subject: ANGIOLOGIA / CARDIOLOGIA Year: 2024 Document type: Article Affiliation country: Spain Country of publication: United States